Please note that the ANZCTR website will be unavailable from 1:00pm until 2:30pm (AEST) on Thursday 31st July for website maintenance.

Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12625000743460
Ethics application status
Approved
Date submitted
28/05/2025
Date registered
15/07/2025
Date last updated
15/07/2025
Date data sharing statement initially provided
15/07/2025
Type of registration
Prospectively registered

Titles & IDs
Public title
The feasibility of yoga therapy for people with lung cancer: A pilot randomised controlled study
Scientific title
The feasibility of yoga therapy for people with lung cancer: A pilot randomised controlled study
Secondary ID [1] 314451 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Cancer 337489 0
Condition category
Condition code
Cancer 333854 333854 0 0
Lung - Non small cell
Physical Medicine / Rehabilitation 333980 333980 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This study is a pilot and feasibility randomised controlled trial examining the effects of yoga on individuals with lung cancer who experience dyspnoea. Participants will be invited to join an 8-week yoga program. Each week, participants are required to attend two yoga sessions: one in-person session (60 minutes) at the NICM Health Research Institute in Westmead and one live online session (approximately 60 minutes) conducted via ZOOM. Additionally, participants have the option to attend a third online yoga session (approximately 60 minutes), which will be scheduled on a specific day and time each week. Attendance at this third session is voluntary.

Before starting the group classes, all participants will receive an online one-on-one introductory session. This session will help them become familiar with using ZOOM and ensure that they can see and be seen clearly by the yoga teacher during online sessions.

The yoga intervention is based on a Delphi study conducted with expert yoga therapists experienced in working with respiratory diseases, including lung cancer. The sequence of yoga postures and techniques used in the group sessions will be standardized across participants to ensure consistency. However, participants will also be encouraged to engage in brief, home-based yoga practices, consisting of a short, simple 10-minute routine that focuses on breathing exercises and relaxation techniques. These home practices are designed to be easy to follow and non-strenuous, promoting regular engagement and symptom management.

All yoga classes will be led by a qualified yoga therapist, with the support of two substitute teachers as needed. For both face-to-face and online sessions, the maximum group size is 5 participants and a qualified yoga therapist leading the session. The weekly sessions (both in-person and online) will include a range of low-intensity techniques, such as:
- Physical postures and movements (e.g., seated spinal twist, supported bridge pose, gentle chest openers)
- Breathing exercises (e.g., diaphragmatic breathing, alternate nostril breathing)
- Relaxation and mindfulness techniques
- Meditation practices (Om meditation).

The overall intensity of the sessions will be low to moderate and will be assessed using the Borg Rating of Perceived Exertion (RPE) scale. Participants will be advised to avoid any movements that cause discomfort or shortness of breath, and sessions will be adapted accordingly.

Participants will receive written and video instructions for the home practices and will be asked to document their engagement in a weekly yoga diary.

Adherence to the intervention will be monitored through:
- Attendance checklists for each group session (including the optional third session)
- Weekly yoga diaries to record home-based practice (duration and frequency) and any adverse events
- Regular phone check-ins (after the first session, then weekly) to assess health status, motivation, and barriers to practice
- Email or text reminders to encourage continued participation

All group sessions (both face-to-face and online) will be video recorded. Baseline measures will be taken in week 0, and final assessments will be conducted in week 9, at least 48 hours after the last scheduled yoga session.
Intervention code [1] 331072 0
Lifestyle
Intervention code [2] 331176 0
Rehabilitation
Comparator / control treatment
The control group will be required to complete all assessment procedures but will be given no specific instructions for yoga or access to yoga therapy classes (i.e. usual care). In addition, all participants will receive a Cancer Council booklet (Victoria, 2021) to help them better understand optimal care. Video recordings of all instructed yoga sessions (in-person and online) will be provided to both group participants at the end of the study (i.e. after the final assessment).
Control group
Active

Outcomes
Primary outcome [1] 341640 0
Feasibility
Timepoint [1] 341640 0
Feasibility assessed at the end of the study
Primary outcome [2] 341642 0
Adverse events
Timepoint [2] 341642 0
Weekly until completion of the 8-week intervention.
Primary outcome [3] 341936 0
Adherence
Timepoint [3] 341936 0
Adherence assessed at completion of the 8-week intervention.
Secondary outcome [1] 448178 0
Dyspnoea
Timepoint [1] 448178 0
At baseline and week 9 post-intervention commencement
Secondary outcome [2] 448179 0
Quality of life
Timepoint [2] 448179 0
At baseline and week 9 post-intervention commencement
Secondary outcome [3] 448180 0
Exercise Capacity
Timepoint [3] 448180 0
At baseline and week 9 post-intervention commencement
Secondary outcome [4] 448181 0
Pulmonary Functions
Timepoint [4] 448181 0
At baseline and week 9 post-intervention commencement
Secondary outcome [5] 448182 0
Depression and Anxiety (Composite Outcome)
Timepoint [5] 448182 0
At baseline and week 9 post-intervention commencement
Secondary outcome [6] 448183 0
Peripheral Muscle Strength
Timepoint [6] 448183 0
At baseline and week 9 post-intervention commencement
Secondary outcome [7] 448184 0
Blood biomarkers
Timepoint [7] 448184 0
At baseline and week 9 post-intervention commencement
Secondary outcome [8] 448185 0
Acceptability
Timepoint [8] 448185 0
At completion of the 8-week intervention
Secondary outcome [9] 448186 0
Response shift
Timepoint [9] 448186 0
At completion of the 8-week intervention
Secondary outcome [10] 448187 0
Recall bias of participants for quality of life prescribed at the beginning of the intervention.
Timepoint [10] 448187 0
Weekly until completion of the 8-week intervention.

Eligibility
Key inclusion criteria
1) 18 years of age or older;
2) diagnosed with any stages of non-small cell lung cancer who completed their last treatment 6 weeks ago);
3) currently experiencing dyspnoea (NRS equal to 3 or greater);
4) sufficient English to understand research procedures and provide written informed consent;
5) able to engage in yoga therapy independently (ECOG equals 0,1 or 2);
6) willing and available to complete all research procedures, including the 1-day face-to-face and 1 online yoga sessions per week.
(NRS: The 0-10 Numerical Rating Scale for dyspnoea is a subjective measurement tool used to assess the severity of a patient's dyspnoea. It asks the patient to rate their dyspnoea on a scale of 0 to 10, where 0 indicates no dyspnoea, and 10 indicates the most severe dyspnoea imaginable (Wysham et al., 2015); ECOG (Eastern Cooperative Oncology Group) Performance Status is a scale used to assess a patient's overall functional status and ability to carry out daily activities, particularly in cancer care. It ranges from 0 to 5, with 0 indicating that the patient is fully active and can carry out all normal activities without restriction and five indicating that the patient is deceased (Popovic et al., 2018)).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1) presence of any disease (comorbidities) that interferes with physical activity (eg. Severe COPD, symptomatic heart failure);
2) mental illnesses, serious cognitive disorders, speech disorders;
3) have been undertaking yoga classes or a personal yoga practice, an average of more than once a week, over the past three months.
4) Life expectancy < 3 months

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The allocation sequence will be kept confidential by using a secure, web-based randomisation system. This ensures that both investigators and participants are unaware of the forthcoming allocations, effectively preventing selection bias by maintaining allocation concealment until the assignment occurs.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomly assigned to either the yoga group or the control group using block randomisation, with block lengths varying randomly. This process will be stratified by gender during the study period. The randomisation sequence will be generated using an online randomisation tool.
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 319294 0
Government body
Name [1] 319294 0
Turkish Republic Ministry of National Education
Country [1] 319294 0
Turkey
Primary sponsor type
Government body
Name
Turkish Republic Ministry of National Education
Address
Country
Turkey
Secondary sponsor category [1] 321767 0
University
Name [1] 321767 0
Western Sydney University
Address [1] 321767 0
Country [1] 321767 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 317593 0
Western Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 317593 0
Ethics committee country [1] 317593 0
Australia
Date submitted for ethics approval [1] 317593 0
30/08/2024
Approval date [1] 317593 0
25/02/2025
Ethics approval number [1] 317593 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 141522 0
A/Prof Bobby Cheema
Address 141522 0
Western Sydney University School of Health Sciences Building 24, 183 Narellan Road Campbelltown NSW 2560 Australia
Country 141522 0
Australia
Phone 141522 0
+61 2 4620 3795
Fax 141522 0
Email 141522 0
Contact person for public queries
Name 141523 0
Bobby Cheema
Address 141523 0
Western Sydney University School of Health Sciences Building 24, 183 Narellan Road Campbelltown NSW 2560 Australia
Country 141523 0
Australia
Phone 141523 0
+61 2 4620 3795
Fax 141523 0
Email 141523 0
Contact person for scientific queries
Name 141524 0
Bobby Cheema
Address 141524 0
Western Sydney University School of Health Sciences Building 24, 183 Narellan Road Campbelltown NSW 2560 Australia
Country 141524 0
Australia
Phone 141524 0
+61 2 4620 3795
Fax 141524 0
Email 141524 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.